Royalty Pharma 

Yahoo Finance • 2 days ago

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings?

Royalty Pharma has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 31.5% and now trades at $45.91. This performance may have investors wondering how to approach the situation. Is now... Full story

Yahoo Finance • 3 days ago

Moderna stands as the best performing large-cap healthcare stock YTD

[Heart Health Concept] Eoneren/E+ via Getty Images U.S. large-cap healthcare stocks have delivered modest year-to-date gains in 2026, holding steady into March amid its defensive appeal. Below is a list of the top 10 large-cap healthcare... Full story

Yahoo Finance • 4 days ago

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of... Full story

Yahoo Finance • 6 days ago

How The Royalty Pharma (RPRX) Story Is Shifting With New Deals And Updated Expectations

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Royalty Pharma’s updated fair value price target now sits at US$51.56, compared with the previous US$51.00 level. Anal... Full story

Yahoo Finance • 24 days ago

Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule

Royalty Pharma (NASDAQ:RPRX) is one of the dirt cheap stocks to buy now. On February 11, Royalty Pharma reported a year of robust financial performance in 2025, marked by a 16% increase in total portfolio receipts and an 18% jump in Q4 alo... Full story

Yahoo Finance • 25 days ago

Zymeworks Q4 Earnings Call Highlights

Zymeworks logo Zymeworks Offers Hope for More than Just Long-Term Investors Zymeworks (NASDAQ:ZYME) executives used the company’s fourth-quarter 2025 results call to highlight updated clinical data for its partnered HER2 antibody zanidat... Full story

Yahoo Finance • 25 days ago

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the comp... Full story

Yahoo Finance • 25 days ago

Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma

(RTTNews) - Zymeworks Inc. (ZYME), a clinical-stage biopharmaceutical company, on Monday entered into a $250 million royalty funding agreement with Royalty Pharma plc (RPRX), a buyer of biopharmaceutical royalties, through a non-recourse r... Full story

Yahoo Finance • 25 days ago

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per t... Full story

Yahoo Finance • 25 days ago

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per t... Full story

Yahoo Finance • 25 days ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Zymeworks Inc. Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with potent... Full story

Yahoo Finance • 29 days ago

Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET. The webcast wil... Full story

Yahoo Finance • last month

Patient Capital Bet Heavily on Chime Financial (CHYM) With a 2.04 Million Share Purchase

What happened According to a Securities and Exchange Commission (SEC) filing dated Feb. 13, 2026, Patient Capital Management, LLC initiated a new position in Chime Financial (NASDAQ:CHYM), acquiring approximately 2,035,112 shares during t... Full story

Yahoo Finance • last month

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Shopify (SHOP [https://seekingalpha.com/symbol/SHOP]) * McDonald's Corporation (MCD [https://seekingalpha.com/symbol/MCD]) * The Kraft Heinz Company (KHC [https://seeki... Full story

Yahoo Finance • 3 months ago

Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi

[Roll of dollars with sign royalties and keyboard.] designer491 * Royalty Pharma (RPRX [https://seekingalpha.com/symbol/RPRX]) has acquired from PTC Therapeutics (PTCT [https://seekingalpha.com/symbol/PTCT]) its remaining royalty intere... Full story

Yahoo Finance • 3 months ago

Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones

Royalty Pharma plc Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020 NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that i... Full story

Yahoo Finance • 4 months ago

Caledonia (Private) Investments Doubles Down on Coursera Stock: Is it Time to Buy?

Key Points Caledonia increased its Coursera stake by 1,935,803 shares, with a net position change of $44.43 million. The transaction accounted for 0.34% of 13F reportable assets under management. Post-trade Coursera position: 9,313,631 sh... Full story

Yahoo Finance • 4 months ago

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future... Full story

Yahoo Finance • 4 months ago

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future... Full story

Yahoo Finance • 4 months ago

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December: Citi’s 2025 Global Healthcare Conference... Full story